In this episode, Ron Lanton examines how geography is becoming a central strategic variable in healthcare, as policy, trade dynamics, and infrastructure increasingly dictate where innovation is developed, manufactured, and commercialized.
This episode of The Ron Lanton Report explores how geography, policy, and capital are converging to redefine where innovation in healthcare actually happens. Rather than treating location as an afterthought once a product is ready to launch, operating environment now sits at the front of the decision tree, determining where assets are developed, manufactured, priced, and sustained over time. The core argument is that companies are no longer just asking what to build, but where that decision should live in a world where policy can shift the ground under an approved product.
The episode moves through several domains where this shift is visible. In market access and pricing, investment decisions are increasingly tethered to policy signals, as seen in how companies like Eli Lilly weigh future investment against evolving pricing and rebate frameworks in markets such as the United Kingdom.
In parallel, trade policy has moved from the background into the core of the business model. Tariffs, trade investigations, and Europe’s push for domestic pharmaceutical production, including measures like the Critical Medicines Act, are reshaping where supply chains are anchored, where manufacturing capacity is built, and how reliably margins can hold over time.
Lanton also examines how regulatory uncertainty and infrastructure constraints are changing growth strategies. When pricing pathways and regulatory expectations are harder to predict, building internally becomes more difficult to plan and finance. As a result, companies are leaning more heavily into partnerships, licensing, collaborations, and acquisitions, not only to grow pipelines, but to reduce exposure to volatile operating conditions.
